The science of psychedelics has come a long way since Drs. Summergrad and Insel met on our stage in 2017. Research into psychedelics has boomed, but six years later fundamental questions remain about mechanisms, efficacy, and policy. Are psychedelics medications for people with a diagnosis or agents to facilitate personal growth? What does the science tell us about benefits and risks? What do we know about the role of psychotherapy or practitioner training ? How should these compounds be regulated? Are there conditions or circumstances that increase the risk of adverse outcomes? Does FDA approval matter? How important is deep experience for providers? And if so, what types of experiences matter? In this session, two of the nation’s psychiatric thought leaders will discuss these questions and more.